Clinical significance of postprandial hyperglycemia

被引:3
作者
Gerich, John E.
Woerle, Hans J.
机构
[1] Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA
[2] Univ Munich, Dept Internal Med 2, Munich, Germany
关键词
postprandial hyperglycemia; cardiovascular disease; treatment recommendations;
D O I
10.1002/ddr.20128
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This review will summarize evidence that postprandial hyperglycemia (1) is an independent risk factor for cardiovascular disease; (2) increases earlier and faster than fasting plasma glucose levels; and (3) contributes more to HbA(1c) levels than fasting hyperglycemia when HbA(1c) levels approach target values and, therefore, is the rate-limiting factor for achieving optimal glycemic control. Finally, treatment recommendations will be presented.
引用
收藏
页码:587 / 590
页数:4
相关论文
共 34 条
[1]   Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].
Ahrén, B ;
Gomis, R ;
Standl, E ;
Mills, D ;
Schweizer, A .
DIABETES CARE, 2004, 27 (12) :2874-2880
[2]  
Alberti KGMM, 1996, DIABETIC MED, V13, P927, DOI 10.1002/(SICI)1096-9136(199611)13:11<927::AID-DIA279>3.0.CO
[3]  
2-E
[4]  
*AM COLL END, 2002, ENDOCR PRACT S1, V8, P5
[5]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[6]  
[Anonymous], 2004, Drugs R D, V5, P35
[7]  
Ceriello A, 2000, DIABETES-METAB RES, V16, P125, DOI 10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO
[8]  
2-4
[9]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[10]   A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors [J].
Chiquette, E ;
Ramirez, G ;
DeFronzo, R .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (19) :2097-2104